Can a single drug replace a long-established curative, albeit brutal, regimen of chemotherapy, radiation, and surgery?
Cancer specialists like me, whether they are medical, surgical, or radiation oncologists spend our lives treating life threatening disease. We generally have a serious and professional demeanor reflective of the world that we choose to inhabit and the circumstances facing our patients that entrust us with their care.
NCI is increasing the R01 payline to the 12th percentile in fiscal year 2023, up from the 11th percentile in FY22—bringing the institute’s payline to a level not seen since 2010.
President Joe Biden mentioned cancer 13 times in his impassioned State of the Union address and placed cancer research at the top of his Unity Agenda—an indication that his administration would continue to prioritize funding for cancer research in fiscal year 2024.
FDA approved Jemperli (dostarlimab-gxly) for adult patients with mismatch repair deficient recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.
Laleh Amiri-Kordestani was named acting associate director for cardio-oncology in the FDA Oncology Center of Excellence. She will also continue her role as the division director for the Division of Oncology 1.
FDA granted accelerated approval to Jaypirca (pirtobrutinib) for relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.
FDA approved Orserdu (elacestrant) for postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
FDA granted first marketing clearance for RefleXion Medical’s SCINTIX biology-guided radiotherapy, a cutting-edge treatment applicable for early and late-stage cancers.
FLAG-003, an investigational small molecule therapy developed by FLAG Therapeutics Inc. for the treatment of diffuse intrinsic pontine glioma—a rare, highly aggressive and difficult to treat brain tumor found in children—has been granted Rare Pediatric Disease designation from FDA.